Literature DB >> 18061150

Complex I deficiency in Parkinson's disease frontal cortex.

W Davis Parker1, Janice K Parks, Russell H Swerdlow.   

Abstract

A study of complex I (NADH:ubiquinone oxidoreductase) activity in Parkinson's disease (PD) brain has identified loss of activity only in substantia nigra although loss of activity of this enzyme has been identified in a number of non-brain tissues. We investigated this paradox by studying complex I and other complexes of the mitochondrial electron transport chain in frontal cortex from PD and aged control brain using a variety of assay conditions and tissue preparations. We found increasingly significant losses of complex I activity in PD frontal cortex as increasingly pure mitochondria were studied. Complexes II, III, and IV were comparable in PD and controls. Inclusion of bovine serum albumin in the assay increased enzyme activity but lessened discrimination between PD and controls. Complex I deficiency in PD brain is not confined to substantia nigra. Methodological issues are critical in demonstrating this loss of activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061150      PMCID: PMC2295283          DOI: 10.1016/j.brainres.2007.10.061

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  27 in total

Review 1.  Mitochondria in Alzheimer's disease.

Authors:  Russell H Swerdlow; Stephen J Kish
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

2.  High frequency of mitochondrial complex I mutations in Parkinson's disease and aging.

Authors:  Rafal Smigrodzki; Janice Parks; W Davis Parker
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

3.  Mitochondrial complex I deficiency in Parkinson's disease.

Authors:  A H Schapira; J M Cooper; D Dexter; P Jenner; J B Clark; C D Marsden
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

4.  Mitochondrial ND5 mutations in idiopathic Parkinson's disease.

Authors:  W Davis Parker; Janice K Parks
Journal:  Biochem Biophys Res Commun       Date:  2005-01-21       Impact factor: 3.575

5.  A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy.

Authors:  W D Parker; C A Oley; J K Parks
Journal:  N Engl J Med       Date:  1989-05-18       Impact factor: 91.245

6.  Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons.

Authors:  S L Budd; L Tenneti; T Lishnak; S A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

7.  A mitochondrial DNA mutation as a cause of Leber's hereditary optic neuropathy.

Authors:  G Singh; M T Lott; D C Wallace
Journal:  N Engl J Med       Date:  1989-05-18       Impact factor: 91.245

8.  Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease.

Authors:  M Gu; J M Cooper; J W Taanman; A H Schapira
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

9.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

10.  Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.

Authors:  I Vyas; R E Heikkila; W J Nicklas
Journal:  J Neurochem       Date:  1986-05       Impact factor: 5.372

View more
  155 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress.

Authors:  Lonnie Schneider; Samantha Giordano; Blake R Zelickson; Michelle S Johnson; Gloria A Benavides; Xiaosen Ouyang; Naomi Fineberg; Victor M Darley-Usmar; Jianhua Zhang
Journal:  Free Radic Biol Med       Date:  2011-09-01       Impact factor: 7.376

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 4.  Stem cell-based models and therapies for neurodegenerative diseases.

Authors:  Shilpa Iyer; Khaled Alsayegh; Sheena Abraham; Raj R Rao
Journal:  Crit Rev Biomed Eng       Date:  2009

Review 5.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

Review 6.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

7.  Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.

Authors:  Taj D King; Buffie Clodfelder-Miller; Keri A Barksdale; Gautam N Bijur
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  Mitochondrial respiratory dysfunction and mutations in mitochondrial DNA in PINK1 familial parkinsonism.

Authors:  Sergio Papa; Anna Maria Sardanelli; Nazzareno Capitanio; Claudia Piccoli
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

10.  Decylubiquinone increases mitochondrial function in synaptosomes.

Authors:  Jayne E Telford; Seán M Kilbride; Gavin P Davey
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.